SMT202000643T1 - Anticorpi anti-attivina a e loro usi - Google Patents

Anticorpi anti-attivina a e loro usi

Info

Publication number: SMT202000643T1
Authority: SM; San Marino
Prior art keywords: activin; antibodies
Prior art date: 2013-07-30

Application number

SM20200643T

Other languages

English (en)

Inventor

Andrew J Murphy

Esther Latres

George D Yancopoulos

Jesper Gromada

Lori C Morton

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-07-30

Filing date

2014-07-30

Publication date

2021-01-05

2014-07-30 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2021-01-05 Publication of SMT202000643T1 publication Critical patent/SMT202000643T1/it

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

SM20200643T 2013-07-30 2014-07-30 Anticorpi anti-attivina a e loro usi SMT202000643T1 (it)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US201361859926P	2013-07-30	2013-07-30
US201361864036P	2013-08-09	2013-08-09
US201361911834P	2013-12-04	2013-12-04
US201361913885P	2013-12-09	2013-12-09
PCT/US2014/048957 WO2015017576A1 (en)	2013-07-30	2014-07-30	Anti-activin a antibodies and uses thereof
EP14750421.1A EP3027209B1 (en)	2013-07-30	2014-07-30	Anti-activin a antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
SMT202000643T1 true SMT202000643T1 (it)	2021-01-05

Family

ID=52427866

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM20200643T SMT202000643T1 (it)	2013-07-30	2014-07-30	Anticorpi anti-attivina a e loro usi

Country Status (28)

Country	Link
US (4)	US9718881B2 (it)
EP (4)	EP4062937A1 (it)
JP (6)	JP6581085B2 (it)
KR (2)	KR102440044B1 (it)
CN (2)	CN105592858B (it)
AU (2)	AU2014296243B2 (it)
BR (1)	BR112016002164B1 (it)
CA (1)	CA2920071C (it)
CL (1)	CL2016000251A1 (it)
CY (1)	CY1123788T1 (it)
DK (1)	DK3027209T3 (it)
EA (1)	EA037926B1 (it)
ES (1)	ES2827673T3 (it)
HR (1)	HRP20201729T1 (it)
HU (1)	HUE052518T2 (it)
IL (2)	IL243822B (it)
LT (1)	LT3027209T (it)
MX (2)	MX371498B (it)
PH (1)	PH12016500182B1 (it)
PT (1)	PT3027209T (it)
RS (1)	RS61124B1 (it)
SG (1)	SG11201600731WA (it)
SI (1)	SI3027209T1 (it)
SM (1)	SMT202000643T1 (it)
TW (2)	TW201920262A (it)
UY (1)	UY35682A (it)
WO (1)	WO2015017576A1 (it)
ZA (1)	ZA201601294B (it)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
EP2781222B1 (en)	2005-11-23	2017-08-02	Acceleron Pharma, Inc.	Activin-actriia antagonists in use for promoting bone growth
CL2007002567A1 (es)	2006-09-08	2008-02-01	Amgen Inc	Proteinas aisladas de enlace a activina a humana.
US8895016B2 (en)	2006-12-18	2014-11-25	Acceleron Pharma, Inc.	Antagonists of activin-actriia and uses for increasing red blood cell levels
CA2677007A1 (en)	2007-02-01	2008-08-07	Acceleron Pharma Inc.	Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201803890A (zh)	2007-02-02	2018-02-01	艾瑟勒朗法瑪公司	衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2481415B1 (en)	2007-02-09	2019-09-11	Acceleron Pharma Inc.	Pharmaceutical compositions comprising Activin-ActRIIA antagonists
JP2010539236A (ja)	2007-09-18	2010-12-16	アクセルロンファーマ，インコーポレイテッド	アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用
TWI626945B (zh)	2008-08-14	2018-06-21	艾瑟勒朗法瑪公司	使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en)	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
EP3290439B1 (en)	2009-06-12	2020-09-02	Acceleron Pharma Inc.	Truncated actriib-fc fusion proteins
EP3332796A1 (en)	2009-11-17	2018-06-13	Acceleron Pharma Inc.	Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JO3340B1 (ar)	2010-05-26	2019-03-13	Regeneron Pharma	مضادات حيوية لـعامل تمايز النمو 8 البشري
KR20130132824A (ko)	2010-11-08	2013-12-05	악셀레론 파마 인코포레이티드	Actriia 결합제 및 이의 용도
JP6177249B2 (ja)	2011-11-14	2017-08-09	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法
US10195249B2 (en)	2012-11-02	2019-02-05	Celgene Corporation	Activin-ActRII antagonists and uses for treating bone and other disorders
TW201920262A (zh) *	2013-07-30	2019-06-01	美商再生元醫藥公司	抗活化素ａ之抗體及其用途
MA40008A (fr)	2014-06-13	2021-05-05	Acceleron Pharma Inc	Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
US20160075772A1 (en) *	2014-09-12	2016-03-17	Regeneron Pharmaceuticals, Inc.	Treatment of Fibrodysplasia Ossificans Progressiva
WO2016145206A1 (en)	2015-03-10	2016-09-15	Regeneron Pharmaceuticals, Inc.	Aseptic piercing system and method
EA039118B1 (ru) *	2015-04-01	2021-12-07	Ридженерон Фармасьютикалз, Инк.	Способ лечения прогрессирующей оссифицирующей фибродисплазии
WO2016168613A1 (en)	2015-04-15	2016-10-20	Regeneron Pharmaceuticals, Inc.	Methods of increasing strength and functionality with gdf8 inhibitors
EP3288976B1 (en)	2015-04-29	2020-04-08	Regeneron Pharmaceuticals, Inc.	Treatment of fibrodysplasia ossificans progressiva
TW202417497A (zh) *	2015-10-12	2024-05-01	美商再生元醫藥公司	活化瘦素受體的抗原結合蛋白
US11542332B2 (en)	2016-03-26	2023-01-03	Bioatla, Inc.	Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US20180008672A1 (en)	2016-07-08	2018-01-11	Regeneron Pharmaceuticals, Inc.	Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
CN116531490A (zh)	2016-07-15	2023-08-04	阿塞勒隆制药公司	用于治疗肺高血压的组合物和方法
CA3039074A1 (en) *	2016-10-05	2018-04-12	Acceleron Pharma Inc.	Compositions and method for treating kidney disease
EP3525820A4 (en) *	2016-10-17	2020-09-16	Vanderbilt University	ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS AND THEIR USE METHODS
CN119241685A (zh) *	2016-11-10	2025-01-03	科乐斯疗法公司	激活素受体iia型变体及其使用方法
ES2919934T3 (es)	2017-05-05	2022-07-29	Regeneron Pharma	Autoinyector y procedimientos de uso relacionados
CA3063588A1 (en) *	2017-06-01	2018-12-06	Regeneron Pharmaceuticals, Inc.	Human antibodies to bet v 1 and methods of use thereof
WO2023154672A2 (en) *	2022-02-14	2023-08-17	Ohio University	Methods for regulating muscle performance using fat specific protein 27 (fsp27) compositions
DE102018103302A1 (de) *	2018-02-14	2019-08-14	Noonee Ag	Tragbare Sitzhaltungshilfevorrichtung
KR20200128125A (ko)	2018-03-01	2020-11-11	리제너론 파아마슈티컬스, 인크.	신체 조성을 변경하기 위한 방법
LT3773713T (lt)	2018-04-06	2025-08-25	Regeneron Pharmaceuticals, Inc.	Leptino receptoriaus agonistinis antikūnas, skirtas kaulų masės didinimui subjektui, kuriam pasireiškia medžiagų apykaitos sutrikimas arba hipoleptinemija
US11419319B2 (en)	2018-06-13	2022-08-23	Regeneran Pharmaceuticals, Inc.	Genetically modified rodent with an inducible ACVR1 mutation in exon 7 that causes ectopic bone formation
MX2021007394A (es)	2018-12-18	2021-07-15	Regeneron Pharma	Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a.
AU2020284038B2 (en)	2019-05-30	2026-05-14	Acceleron Pharma Inc.	ActRII-binding proteins and uses thereof
IL294611B1 (en)	2020-01-08	2026-05-01	Regeneron Pharmaceuticals Inc	Treatment of fibrodysplasia ossificans progressive
KR20210095781A (ko)	2020-01-24	2021-08-03	주식회사 에이프릴바이오	항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
JP2023519100A (ja)	2020-02-11	2023-05-10	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	抗ａｃｖｒ１抗体およびその使用
EP4142769A4 (en)	2020-04-28	2024-05-15	Acceleron Pharma Inc.	ACTRII PROTEINS AND USE IN THE TREATMENT OF POSTCAPILLARY PULMONARY HYPERTENSION
IL299103A (en)	2020-06-18	2023-02-01	Regeneron Pharma	Formulations of activin A antibody and methods of its use
CA3177918A1 (en)	2020-07-01	2022-01-06	Amanda ATANASIO	Methods of treating allergy using anti-bet v 1 antibodies
JP2023539107A (ja) *	2020-08-20	2023-09-13	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	アクチビンａアンタゴニストによる心機能障害及びｃｏｖｉｄ－１９の予防及び治療方法
AU2021377176A1 (en) *	2020-11-11	2023-06-22	Hq Han	Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
WO2023022968A2 (en) *	2021-08-16	2023-02-23	Acceleron Pharma Inc.	Compositions and methods for treating renal diseases or conditions
EP4419553A1 (en)	2021-10-18	2024-08-28	BYOMass Inc.	Anti-activin a antibodies, compositions and uses thereof
USD1007676S1 (en)	2021-11-16	2023-12-12	Regeneron Pharmaceuticals, Inc.	Wearable autoinjector
EP4472733A1 (en)	2022-01-31	2024-12-11	BYOMass Inc.	Myeloproliferative conditions
TWI819587B (zh) *	2022-04-29	2023-10-21	洪慧妤	用於預防癌症所引發的肌少症之組合物及組合物於製造供預防癌症所引發之肌少症食品的用途
KR20250075642A (ko)	2022-09-21	2025-05-28	리제너론 파아마슈티컬스, 인크.	비만, 당뇨병 및 간 기능 장애를 치료하는 방법
KR20260025363A (ko)	2023-06-16	2026-02-24	리제너론 파아마슈티컬스, 인크.	의료 디바이스 패키징 및 관련 방법
CN116990523A (zh) *	2023-06-30	2023-11-03	重庆医科大学	骨形态蛋白-9作为生物标志物在脓毒血症诊断、预后、疗效评估及治疗中的用途
WO2025075970A1 (en)	2023-10-02	2025-04-10	Regeneron Pharmaceuticals, Inc.	Drug delivery device safety system
US20260000758A1 (en) *	2024-06-28	2026-01-01	Regeneron Pharmaceuticals, Inc.	Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof
WO2026037938A1 (en)	2024-08-16	2026-02-19	Protuoso Pte. Ltd.	Fusion proteins comprising a glp-1 receptor agonist and a myostatin pathway inhibitor

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE255131T1 (de)	1991-06-14	2003-12-15	Genentech Inc	Humanisierter heregulin antikörper
US5994618A (en)	1997-02-05	1999-11-30	Johns Hopkins University School Of Medicine	Growth differentiation factor-8 transgenic mice
ES2201076T3 (es)	1993-03-19	2004-03-16	The Johns Hopkins University School Of Medicine	Factor-8 de diferenciacion del crecimiento.
DE69941116D1 (de)	1998-05-06	2009-08-27	Metamorphix Inc	G von gdf-8
SK722002A3 (en)	1999-07-20	2003-02-04	Pharmexa As	Method for down-regulating GDF-8 activity
US7320789B2 (en)	2001-09-26	2008-01-22	Wyeth	Antibody inhibitors of GDF-8 and uses thereof
US7241444B2 (en)	2002-01-18	2007-07-10	Pierre Fabre Medicament	Anti-IGF-IR antibodies and uses thereof
US7261893B2 (en)	2002-10-22	2007-08-28	Wyeth	Neutralizing antibodies against GDF-8 and uses therefor
JP5110877B2 (ja)	2003-06-02	2012-12-26	ワイス・エルエルシー	神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用
CN1902221A (zh)	2003-12-31	2007-01-24	先灵-普劳有限公司	基于中和表位的生长增强疫苗
US7456149B2 (en)	2004-03-02	2008-11-25	Acceleron Pharma, Inc.	ALK7 and myostatin inhibitors and uses thereof
US20070178095A1 (en)	2004-03-23	2007-08-02	Eli Lilly And Company	Anti-myostatin antibodies
WO2005103081A2 (en)	2004-04-20	2005-11-03	Genmab A/S	Human monoclonal antibodies against cd20
MX2007000976A (es)	2004-08-12	2007-04-10	Wyeth Corp	Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion.
NZ538097A (en)	2005-02-07	2006-07-28	Ovita Ltd	Method and compositions for improving wound healing
EP1877075A4 (en)	2005-04-25	2008-07-30	Pfizer	ANTIBODY TO MYOSTATIN
PL2407486T3 (pl)	2005-08-19	2018-05-30	Wyeth Llc	Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
ES2533464T3 (es)	2005-10-06	2015-04-10	Eli Lilly And Company	Anticuerpos anti-miostatina
UA92504C2 (en)	2005-10-12	2010-11-10	Эли Лилли Энд Компани	Anti-myostatin monoclonal antibody
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
CN101370511B (zh) *	2005-11-23	2015-07-01	阿塞勒隆制药公司	Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
EP1968621A2 (en)	2005-12-06	2008-09-17	Amgen Inc.	Uses of myostatin antagonists
NZ587107A (en)	2006-06-02	2012-05-25	Regeneron Pharma	High affinity antibodies to human il-6 receptor
PL2066695T3 (pl)	2006-09-05	2013-08-30	Lilly Co Eli	Przeciwciała przeciwko miostatynie
CL2007002567A1 (es) *	2006-09-08	2008-02-01	Amgen Inc	Proteinas aisladas de enlace a activina a humana.
US7947646B2 (en)	2007-03-06	2011-05-24	Amgen Inc.	Variant activin receptor polypeptides
PE20091163A1 (es)	2007-11-01	2009-08-09	Wyeth Corp	Anticuerpos para gdf8
AR069165A1 (es)	2007-11-05	2010-01-06	Novartis Ag	Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia
TWI626945B (zh)	2008-08-14	2018-06-21	艾瑟勒朗法瑪公司	使用ｇｄｆ阱以增加紅血球水平
NZ627111A (en) *	2008-11-26	2015-10-30	Amgen Inc	Variants of activin iib receptor polypeptides and uses thereof
AR074777A1 (es)	2008-12-19	2011-02-09	Glaxo Group Ltd	Proteinas de union a antigeno
CA2993053A1 (en)	2009-04-27	2010-11-04	Novartis Ag	Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
LT2975051T (lt)	2009-06-26	2021-07-12	Regeneron Pharmaceuticals, Inc.	Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
EP3332796A1 (en)	2009-11-17	2018-06-13	Acceleron Pharma Inc.	Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JO3340B1 (ar)	2010-05-26	2019-03-13	Regeneron Pharma	مضادات حيوية لـعامل تمايز النمو 8 البشري
KR20130132824A (ko)	2010-11-08	2013-12-05	악셀레론 파마 인코포레이티드	Actriia 결합제 및 이의 용도
JP6177249B2 (ja) *	2011-11-14	2017-08-09	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法
GR1007832B (el)	2011-11-21	2013-02-14	Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων,	Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
MY177331A (en)	2012-06-15	2020-09-12	Pfizer	Improved antagonist antibodies against gdf-8 and uses therefor
SG11201505960VA (en)	2013-02-01	2015-08-28	Santa Maria Biotherapeutics Inc	Administration of an anti-activin-a compound to a subject
TW201920262A (zh)	2013-07-30	2019-06-01	美商再生元醫藥公司	抗活化素ａ之抗體及其用途
US20160075772A1 (en)	2014-09-12	2016-03-17	Regeneron Pharmaceuticals, Inc.	Treatment of Fibrodysplasia Ossificans Progressiva
WO2016168613A1 (en)	2015-04-15	2016-10-20	Regeneron Pharmaceuticals, Inc.	Methods of increasing strength and functionality with gdf8 inhibitors
KR20200128125A (ko) *	2018-03-01	2020-11-11	리제너론 파아마슈티컬스, 인크.	신체 조성을 변경하기 위한 방법

2014
- 2014-07-28 TW TW107147614A patent/TW201920262A/zh unknown
- 2014-07-28 TW TW103125622A patent/TWI655207B/zh active
- 2014-07-30 LT LTEP14750421.1T patent/LT3027209T/lt unknown
- 2014-07-30 CN CN201480049484.7A patent/CN105592858B/zh active Active
- 2014-07-30 SI SI201431693T patent/SI3027209T1/sl unknown
- 2014-07-30 AU AU2014296243A patent/AU2014296243B2/en active Active
- 2014-07-30 SG SG11201600731WA patent/SG11201600731WA/en unknown
- 2014-07-30 EA EA201690243A patent/EA037926B1/ru unknown
- 2014-07-30 EP EP22171329.0A patent/EP4062937A1/en active Pending
- 2014-07-30 CN CN202111054074.XA patent/CN113845594A/zh active Pending
- 2014-07-30 UY UY35682A patent/UY35682A/es active IP Right Grant
- 2014-07-30 MX MX2016001394A patent/MX371498B/es active IP Right Grant
- 2014-07-30 BR BR112016002164-9A patent/BR112016002164B1/pt active IP Right Grant
- 2014-07-30 ES ES14750421T patent/ES2827673T3/es active Active
- 2014-07-30 EP EP20176858.7A patent/EP3730151A1/en active Pending
- 2014-07-30 EP EP14750421.1A patent/EP3027209B1/en active Active
- 2014-07-30 KR KR1020217033330A patent/KR102440044B1/ko active Active
- 2014-07-30 HR HRP20201729TT patent/HRP20201729T1/hr unknown
- 2014-07-30 PH PH1/2016/500182A patent/PH12016500182B1/en unknown
- 2014-07-30 RS RS20201414A patent/RS61124B1/sr unknown
- 2014-07-30 PT PT147504211T patent/PT3027209T/pt unknown
- 2014-07-30 EP EP22171327.4A patent/EP4059520A1/en active Pending
- 2014-07-30 SM SM20200643T patent/SMT202000643T1/it unknown
- 2014-07-30 KR KR1020167005280A patent/KR102315694B1/ko active Active
- 2014-07-30 CA CA2920071A patent/CA2920071C/en active Active
- 2014-07-30 JP JP2016531870A patent/JP6581085B2/ja active Active
- 2014-07-30 US US14/447,444 patent/US9718881B2/en active Active
- 2014-07-30 MX MX2020001201A patent/MX379446B/es unknown
- 2014-07-30 DK DK14750421.1T patent/DK3027209T3/da active
- 2014-07-30 HU HUE14750421A patent/HUE052518T2/hu unknown
- 2014-07-30 WO PCT/US2014/048957 patent/WO2015017576A1/en not_active Ceased
2016
- 2016-01-28 IL IL24382216A patent/IL243822B/en active IP Right Grant
- 2016-01-29 CL CL2016000251A patent/CL2016000251A1/es unknown
- 2016-02-25 ZA ZA2016/01294A patent/ZA201601294B/en unknown
2017
- 2017-06-29 US US15/637,867 patent/US10526403B2/en active Active
2019
- 2019-08-28 JP JP2019155139A patent/JP6923602B2/ja active Active
- 2019-10-27 IL IL270218A patent/IL270218B/en active IP Right Grant
2020
- 2020-02-07 AU AU2020200892A patent/AU2020200892B2/en active Active
- 2020-07-10 US US16/926,481 patent/US20210163583A1/en not_active Abandoned
- 2020-12-01 CY CY20201101138T patent/CY1123788T1/el unknown
2021
- 2021-07-28 JP JP2021122976A patent/JP7440464B2/ja active Active
2022
- 2022-06-29 JP JP2022104218A patent/JP7496387B2/ja active Active
- 2022-08-09 JP JP2022126761A patent/JP7589200B2/ja active Active
- 2022-11-28 US US18/059,315 patent/US20230312699A1/en active Pending
2024
- 2024-11-12 JP JP2024197067A patent/JP2025024066A/ja active Pending

Also Published As

Publication number	Publication date
DK3027209T3 (da)	2020-11-02
HRP20201729T1 (hr)	2020-12-25
AU2014296243B2 (en)	2019-11-21
US20230312699A1 (en)	2023-10-05
JP7589200B2 (ja)	2024-11-25
AU2014296243A1 (en)	2016-03-03
JP2025024066A (ja)	2025-02-19
JP2016528232A (ja)	2016-09-15
EP4062937A1 (en)	2022-09-28
JP2020011965A (ja)	2020-01-23
US20180155416A1 (en)	2018-06-07
ZA201601294B (en)	2017-05-31
CA2920071C (en)	2023-05-23
SG11201600731WA (en)	2016-02-26
NZ716854A (en)	2022-03-25
JP2022160619A (ja)	2022-10-19
IL243822A0 (en)	2016-04-21
EP3027209B1 (en)	2020-09-02
WO2015017576A1 (en)	2015-02-05
JP7496387B2 (ja)	2024-06-06
KR102440044B1 (ko)	2022-09-06
HK1225322A1 (en)	2017-09-08
IL270218B (en)	2021-01-31
PH12016500182B1 (en)	2024-04-12
JP7440464B2 (ja)	2024-02-28
CN113845594A (zh)	2021-12-28
KR102315694B1 (ko)	2021-10-21
CN105592858B (zh)	2021-10-01
EP4059520A1 (en)	2022-09-21
RS61124B1 (sr)	2020-12-31
MX379446B (es)	2025-03-10
KR20160030581A (ko)	2016-03-18
CY1123788T1 (el)	2022-03-24
PH12016500182A1 (en)	2016-04-25
CL2016000251A1 (es)	2017-07-14
NZ754959A (en)	2022-03-25
US20150037339A1 (en)	2015-02-05
UY35682A (es)	2015-02-27
PT3027209T (pt)	2020-10-22
JP2021176887A (ja)	2021-11-11
AU2020200892A1 (en)	2020-03-05
MX2016001394A (es)	2016-08-03
EA201690243A1 (ru)	2016-06-30
JP2022130593A (ja)	2022-09-06
LT3027209T (lt)	2020-12-28
JP6923602B2 (ja)	2021-08-25
BR112016002164A2 (pt)	2017-09-12
MX371498B (es)	2020-01-31
EP3027209A1 (en)	2016-06-08
EP3730151A1 (en)	2020-10-28
AU2020200892B2 (en)	2022-03-31
HUE052518T2 (hu)	2021-05-28
IL243822B (en)	2019-11-28
CN105592858A (zh)	2016-05-18
US10526403B2 (en)	2020-01-07
SI3027209T1 (sl)	2020-11-30
TW201602133A (zh)	2016-01-16
MX2020001201A (es)	2021-01-28
US20210163583A1 (en)	2021-06-03
BR112016002164B1 (pt)	2023-12-19
ES2827673T3 (es)	2021-05-24
US9718881B2 (en)	2017-08-01
CA2920071A1 (en)	2015-02-05
KR20210129253A (ko)	2021-10-27
TWI655207B (zh)	2019-04-01
JP6581085B2 (ja)	2019-09-25
EA037926B1 (ru)	2021-06-08
TW201920262A (zh)	2019-06-01

Publication	Publication Date	Title
IL261743B (en)	2020-11-30	and their uses 33–il antibodies against
IL261547B (en)	2019-12-31	Antibodies against pesidine and their uses
ZA201601294B (en)	2017-05-31	Anti-activin a antibodies and uses thereof
IL245040A0 (en)	2016-05-31	Antibodies against pdgfr-beta and their uses
IL243974B (en)	2018-06-28	Antibodies against –prlr and uses
ZA201508896B (en)	2019-06-26	Anti-c10orf54 antibodies and uses thereof
SG10201709715RA (en)	2017-12-28	Anti-b7-h5 antibodies and their uses
SG11201509116VA (en)	2015-12-30	Anti-tweakr antibodies and uses thereof
EP2953970A4 (en)	2016-06-29	TRANSTYRETIN ANTIBODIES AND USES THEREOF
HUE049446T2 (hu)	2020-09-28	Anti-FCRH5 antitestek
GB201322583D0 (en)	2014-02-05	Antibodies
IL244043A0 (en)	2016-04-21	Antibodies
GB201308658D0 (en)	2013-06-26	Antibodies
GB201315486D0 (en)	2013-10-16	Antibodies
GB201300706D0 (en)	2013-02-27	Antibody
IL245488B (en)	2020-03-31	Anti- ccl17 antibodies
GB201318283D0 (en)	2013-11-27	Antibodies